TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15876979
Drug: Antihypertensive regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive regimens (various classes)
Study: 11905711
Drug: Preoperative (neoadjuvant)
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative (neoadjuvant) medical therapy
Study: 9137021
Drug: Biojector (needleless
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biojector (needleless injection system)
Study: 3796171
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose amoxicillin (100 mg/kg) followed by placebo every 8 hours for 10 days
Study: 3796171
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of amoxicillin (40 mg/kg/D)
Study: 26582405
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid for 5 consecutive days
Study: 20072737
Drug: Platform-switched implants
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implants
Study: 19865633
Drug: External-hexagon implants
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External-hexagon implants
Study: 15733514
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic cream applied to face
Study: 15733514
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic cream applied to back of hand
Study: 12874415
Drug: 12-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month treatment with IV anti-T-lymphocyte immunoglobulin followed by oral methotrexate 7.5 mg/week (ATG group)
Study: 12874415
Drug: 12-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group)
Study: 10369711
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 microg, subcutaneous injection three times daily for seven days
Study: 10369711
Drug: Octreotide 200
Normalized name: octreotide 200 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 200 microg, subcutaneous injection three times daily for seven days
Study: 10369711
Drug: Placebo, subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, subcutaneous injection three times daily for seven days
Study: 10369711
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Octreotide and Placebo)
Study: 8899313
Drug: Ukrain monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain monotherapy
Study: 8899313
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) and X‐ray therapy
Study: 6407749
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 4 malnourished children for 28 days
Study: 6407749
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition plus enteral nutrition for 4 malnourished children for 28 days
Study: 6407749
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 2 nourished children
Study: 6407749
Drug: Nourished or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nourished or becoming renourished during the first 21 days of therapy
Study: 6407749
Drug: Becoming malnourished
Normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becoming malnourished or remaining malnourished during the first 21 days of therapy
Study: 30914102
Drug: Sodium acetate
Normalized name: Sodium Acetate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium acetate Ringer solution infusion (group A: 4 mL·kg‐1·h‐1, group B: increased by 50%, group C: increased by 100%) for 30 minutes
Study: 30914102
Drug: Sodium acetate
Normalized name: Sodium Acetate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium acetate Ringer solution infusion (group B)
Study: 30914102
Drug: Sodium acetate
Normalized name: Sodium Acetate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium acetate Ringer solution infusion (group A)
Study: 28012569
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (MPA) 80 mg, 2 mL
Study: 28012569
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) 80 mg, 2 mL
Study: 19384218
Drug: N-acetylcysteine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (100 mg/kg bolus; 20 mg.kg.hr infusion until 4 hours after cardiopulmonary bypass)
Study: 15121491
Drug: Spironolactone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (mean dose 32 +/- 16 mg)
Study: 30638544
Drug: Liothyronine (T3)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine (T3) therapy (maximum dosage 15 mcg/m2/die)
Study: 30638544
Drug: Liothyronine (T3)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine (T3) therapy (T3-treated group)
Study: 25198275
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion for less than 12 hours
Study: 25198275
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion for 12-18 hours
Study: 25198275
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion for greater than 18 hours
Study: 25198275
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (all durations)
Study: 17317371
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg (in subjects with low HDL cholesterol)
Study: 17317371
Drug: atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 80 mg (in subjects with low HDL cholesterol)
Study: 15063607
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/fenofibrate
Study: 2133472
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by a dentist
Study: 2133472
Drug: Craniomandibular disorder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniomandibular disorder treatment group
Study: 2133472
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by a neurologist
Study: 28384065
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 21 days)
Study: 25554623
Drug: D-serine (DSR)
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (DSR) 2.1 g orally administered
Study: 24283280
Drug: Dentifrice quantity
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentifrice quantity (0.5 g vs 1.5 g)
Study: 17143175
Drug: Ramipril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1 mg/kg per day)
Study: 15108979
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion at 4 kJ x kg(‐1) x h(‐1) for 2.5 h combined with skin‐surface warming
Study: 15108979
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion combined with cutaneous cooling
Study: 15108979
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion combined with skin‐surface warming
Study: 15108979
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion combined with cutaneous cooling
Study: 8031555
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg, 20 mg)
Study: 8031555
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg, 8 mg)
Study: 2029111
Drug: Methotrexate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5 mg weekly, increased to 15 mg after 8 weeks if clinically effective)
Study: 2029111
Drug: Azathioprine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (100 mg daily, increased to 150 mg after 8 weeks if clinically effective)
Study: 318908
Drug: Butorphanol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.5 mg
Study: 318908
Drug: Butorphanol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1.0 mg
Study: 318908
Drug: Meperidine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 20 mg
Study: 318908
Drug: Butorphanol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.5 mg and 1.0 mg
Study: 28553076
Drug: 2.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg/kg palonosetron
Study: 28553076
Drug: 7.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg/kg palonosetron
Study: 28553076
Drug: 2.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg/kg palonosetron and 15 μg/kg droperidol
Study: 25651245
Drug: Oral tenofovir-emtricitabine
Normalized name: emtricitabine / tenofovir disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenofovir-emtricitabine (TDF-FTC)
Study: 25651245
Drug: 1% tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tenofovir (TFV) vaginal gel
Study: 25651245
Drug: Oral TDF-FTC
Normalized name: (-)-FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TDF-FTC
Study: 10028980
Drug: Home-based mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based mass antibiotic treatment (azithromycin, ciprofloxacin, metronidazole)
Study: 10028980
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vitamins/anthelmintic drug)
Study: 8897864
Drug: L-glutamine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (800 mumol.kg-1.h-1)
Study: 8897864
Drug: Glycine (isonitrogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (isonitrogenous infusion)
Study: 1324895
Drug: RT and
Normalized name: Comfort and Ease KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT and daily low dose of cDDP (6 mg/m2)
Study: 6828981
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin gluceptate
Study: 6828981
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole with tobramycin
Study: 28799984
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (60 mg, Xylocaine 10% pump spray)
Study: 28799984
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (chlorhexidine gluconate 0.5% in 70% alcohol base)
Study: 20471117
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rosuvastatin loading before PCI
Study: 18706705
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment before PCI (Control group)
Study: 16564621
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 ml, 20mg/ml lidocaine and 12.5 microg/ml adrenaline)
Study: 16564621
Drug: Saline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1.5 ml, 9 mg/ml NaCl solution) (placebo)
Study: 6537916
Drug: Empiric antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotic treatment for fever
Study: 30105362
Drug: Fludrocortisone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.1 to 0.4 mg per day)
Study: 27438627
Drug: ONS solution
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS solution 2 hours before surgery
Study: 25440377
Drug: 15g/day of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15g/day of E. angustifolia L. medulla for 8 weeks
Study: 25440377
Drug: 15g/day of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15g/day of E. angustifolia L. whole fruit for 8 weeks
Study: 18056193
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 i.v. infusion over 1 hour)
Study: 15957134
Drug: Immediate-Treatment Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-Treatment Group (ITG)
Study: 15957134
Drug: Deferred-Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred-Treatment Group (DTG)
Study: 12107244
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (80 mU/m(2).min) during euglycemic clamp
Study: 12107244
Drug: Matched saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched saline infusion (control group)
Study: 7554700
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg loratadine every morning plus 500 mg erythromycin stearate every 8 hours
Study: 7554700
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg loratadine every morning plus placebo every 8 hours
Study: 7554700
Drug: placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo every morning plus 500 mg erythromycin stearate
Study: 6243916
Drug: Topical ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ampicillin sodium
Study: 30566417
Drug: Second-generation oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-generation oral antipsychotics
Study: 28363637
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg DSM265 1 day before CHMI
Study: 28363637
Drug: Atovaquone-proguanil (250-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone-proguanil (250-100 mg) 1 day before CHMI
Study: 28363637
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg DSM265 7 days before CHMI
Study: 21378389
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (target glucose 80‐120 mg/dl)
Study: 21378389
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose control (target glucose 180 mg/dl or less)
Study: 29549863
Drug: Appetite Awareness
Normalized name: APPETITE SUPPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appetite Awareness Treatment (AAT)
Study: 26130657
Drug: Land-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based therapy (Control group, n=14), 45 minutes per session, five days a week for four weeks
Study: 23632946
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta (IFNβ)‐1a
Study: 18621519
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg twice daily for 5 days
Study: 16085366
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and contingency management (CM)
Study: 12888042
Drug: 0.25 mg/ml
Normalized name: thiram 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/ml ICG
Study: 12888042
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml ICG
Study: 12888042
Drug: 1.25 mg/ml
Normalized name: menthol 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/ml ICG
Study: 12888042
Drug: Control (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.25 mg/ml and 0.5 mg/ml ICG)
Study: 10472355
Drug: Photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon therapy (median dose 60 Gy, range 45 to 65 Gy)
Study: 10472355
Drug: Neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron therapy (median dose 14.1 Gy, range 5.0 to 18.57 Gy)
Study: 10472355
Drug: Mixed-beam irradiation
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-beam irradiation (average dose 36.5 Gy photon and 8.5 Gy neutrons)
Study: 8923090
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon gamma 100 ug subcutaneously daily for up to 21 days
Study: 6760063
Drug: 4.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg/kg theophylline solution administered at 9 a.m.
Study: 6760063
Drug: 4.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg/kg theophylline solution administered at 9 p.m.
Study: 6760063
Drug: 4.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg/kg theophylline solution (both morning and evening)
Study: 30017826
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of vilanterol (25 μg) + fluticasone furoate (100 μg)
Study: 14703410
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy + radiotherapy (GTRT group, n = 16)
Study: 8538479
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (EV, 2 mg/day for 21 days) with cyproterone acetate (CPA, 1 mg/day in the last 10 days of the treatment cycle)
Study: 8538479
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (500 mg/day)
Study: 7333345
Drug: Theolair Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolair Retard 250 mg sustained release tablet
Study: 30419858
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy added to chemo-radiotherapy
Study: 23135413
Drug: Cementless fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cementless fixation with screw augmentation (n=45)
Study: 20193089
Drug: Yoga practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga practice for one hour daily for one week
Study: 18072052
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of polyethylene glycol (PEG) solution
Study: 18072052
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of polyethylene glycol (PEG) solution
Study: 18072052
Drug: Clear liquid
Normalized name: Ensure Clear Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear liquid diet and overnight fast (no PEG solution)
Study: 16271342
Drug: 6‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mg nicotine enemas
Study: 16271342
Drug: 6‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mg nicotine enemas in patients taking mesalamine
Study: 11583888
Drug: GTN, 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN, 0.6 mg/h/24 h for six days
Study: 9622211
Drug: Bemiparin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemiparin (therapeutic subcutaneous doses)
Study: 7888287
Drug: Metoprolol CR/Z0K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/Z0K 100 mg
Study: 7888287
Drug: Metoprolol CR/Z0K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/Z0K 50 mg
Study: 3352163
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAA) infusion
Study: 28835380
Drug: BL-8040 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-8040 (1 mg/kg)
Study: 28835380
Drug: BL-8040 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-8040 (0.5 mg/kg)
Study: 28835380
Drug: BL-8040 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-8040 (0.75 mg/kg)
Study: 23669458
Drug: Programs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programs with culturally responsive policies and assessment and treatment practices
Study: 17226044
Drug: Tibolone (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (21 days treatment)
Study: 15490767
Drug: Couple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple therapy included in inpatient treatment (15 patients)
Study: 15490767
Drug: Standard inpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inpatient treatment without partner therapy (16 patients)
Study: 11902819
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy (oestradiol 2 mg and norethisterone acetate 1 mg per day)
Study: 24235081
Drug: Velcalcetide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velcalcetide 0.5 mg
Study: 24235081
Drug: Velcalcetide 2
Normalized name: Velcalcetide
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Velcalcetide 2 mg
Study: 24235081
Drug: Velcalcetide 5
Normalized name: Velcalcetide
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Velcalcetide 5 mg
Study: 24235081
Drug: Velcalcetide 10
Normalized name: Velcalcetide
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Velcalcetide 10 mg
Study: 22777096
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A control vaccine (n = 102)
Study: 12891099
Drug: Stripping and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stripping and high ligation (S&L)